TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Sees Large Decline in Short Interest

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 49,400 shares, a drop of 61.5% from the February 13th total of 128,400 shares. Approximately 176.4% of the company’s shares are short sold. Based on an average daily volume of 260,900 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright dropped their target price on shares of TC Biopharm from $112.00 to $48.00 and set a “buy” rating for the company in a research report on Friday, December 6th.

TC Biopharm Stock Up 2.4 %

Shares of TC Biopharm stock traded up $0.04 during trading hours on Friday, hitting $1.73. The company’s stock had a trading volume of 44,581 shares, compared to its average volume of 93,059. The stock has a 50 day moving average of $4.66 and a 200 day moving average of $32.57. TC Biopharm has a 12 month low of $1.43 and a 12 month high of $523.20.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.